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Human pluripotent stem cell (hPSC)-derived intestinal organoids (hIOs) form 3D structures
organized into crypt and villus domains, making them an excellent in vitro model system for
studying human intestinal development and disease. However, hPSC-derived hIOs still
require in vivo maturation to fully recapitulate adult intestine, with the mechanism of
maturation remaining elusive. Here, we show that the co-culture with human T lymphocytes
induce the in vitro maturation of hIOs, and identify STAT3-activating interleukin-2 (IL-2) as
the major factor inducing maturation. hIOs exposed to IL-2 closely mimic the adult intestinal
epithelium and have comparable expression levels of mature intestinal markers, as well as
increased intestine-specific functional activities. Even after in vivo engraftment, in vitro-
matured hIOs retain their maturation status. The results of our study demonstrate that
STAT3 signaling can induce the maturation of hIOs in vitro, thereby circumventing the need
for animal models and in vivo maturation.
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The adult intestinal epithelium performs diverse physiolo-gical functions: as a major interface between the interiorand exterior environment of an organism it is responsible
for digestion and nutrient absorption, it presents a mucosal
barrier to microorganisms, and regulates the immune response to
pathogens. These functions are enacted by specialized cell types,
including absorptive enterocytes and the secretory cell types
known as goblet, enteroendocrine, and Paneth cells, which secrete
mucin, hormones and anti-bacterial peptides, respectively1. In
addition to the monolayer of intestinal epithelial cells, the com-
plete intestine contains other cell types, such as fibroblasts,
immune cells, interstitial cells, vascular and lymphatic endothelial
cells, smooth muscle cells, and enteric neurons2, all of which
interact extensively with each other during development to
develop the cooperation necessary for full gut functionality in the
adult3.
Recently, 3D multicellular intestinal organoids (hIOs) have been
developed using either human pluripotent stem cells (hPSCs)4 or
adult intestinal stem cells5 as the source material. hIOs contain crypt-
like and villus-like structures, as well as all four major cell types of the
small intestinal epithelium, so recapitulating the architecture and
cellular diversity of the epithelium. In addition, hIOs exhibit basic
physiological functions like the secretion of mucus and absorption of
amino acids4,6. Once established, hIOs can be passaged in vitro
multiple times for up to 1 year. In contrast to hIOs formed from
adult stem cells, hPSC-derived hIOs are surrounded by a primitive
mesenchyme which can differentiate into smooth muscle, myofi-
broblasts, and fibroblasts during the differentiation protocol, meaning
that hPSC-derived hIOs simultaneously model both the epithelial and
submucosal layers of the human intestine in vitro3. The elucidation of
a stepwise differentiation protocol directing hPSCs towards a func-
tional intestinal epithelium has thus in and of itself greatly improved
our understanding of human intestinal development. However,
despite the significant similarities in structure and function between
hIOs and the intestine, hPSC-derived hIOs still retain immature
characteristics, making them more similar to the fetal intestine7,8.
These immature hIOs can further develop into functionally mature,
adult-like small intestine, but only in vivo following transplantation
into the kidney capsule or when grown as a teratoma in an immu-
nocompromised mouse9,10. The mature small intestine has unique
characteristics, including the expression of the mature stem cell
marker, OLFM4, as well as an upregulated expression of genes
required for digestion, transport, and gut immunity11,12. Currently,
the mechanisms promoting the full maturation of hIO, including the
identity of signaling cues, supporting cell types and the surrounding
environment, are not known.
In this study, we demonstrate that interleukin-2 (IL-2)-secreting
immune cells promote the maturation of hPSC-derived hIOs as part
of an in vitro co-culture system. Further investigations demon-
strated that the activation of STAT3 signaling was crucial for the
in vitro maturation of hIOs. Following in vitro maturation, hIOs
exhibited the characteristics of mature adult intestinal epithelium in
terms of both gene expression profile and diverse functionality. Our
findings thus shed light on the biological mechanism of neonatal
gut development, underlining the importance of interactions
between immune and epithelial cells for the maturation of the gut.
The inclusion of the immune component into the stepwise differ-
entiation protocol to form mature hIOs from hPSCs resolves a
previous limitation of this technology, enabling the use of pre-
established normal and induced hPSCs for studies of adult phy-
siology and diseases of the intestine.
Results
Co-culture with T lymphocytes promotes hIO maturation.
Three hIO lines were derived from hPSCs following a previously
described13,14, stepwise hIO differentiation protocol: one hIO line
was derived from a human embryonic stem cell (hESC) line and
two lines were obtained from fully characterized, integration-free
human induced pluripotent stem cell (hiPSC) lines repro-
grammed from human fibroblasts (Supplementary Fig. 1). As
expected, hPSCs could be efficiently differentiated into definitive
endoderm, hindgut, and hIO fates with their accompanying
characteristic morphologies and the expression of stage-specific
markers (Supplementary Fig. 2a, b and Fig. 1a). During the first
two passages we observed an increase in the expression of
intestinal markers, such as intestinal transcription factors (CDX2,
SOX9, and ISX) and cell type-specific markers, including VIL1
(villin 1 for enterocytes), CHGA (chromogranin A for enter-
oendocrine cells), LYZ (lysozyme for Paneth cells), MUC2 (mucin
2 for goblet cells), and the mesenchymal marker VIM (vimentin),
confirming the specification of hPSCs for an intestinal identity
(Supplementary Fig. 2c). A microarray-based principal compo-
nent analysis (PCA) further confirmed the acquisition of intest-
inal identity by the hIOs over the first two passages (Fig. 1b).
However, as previously reported7, when compared directly to
adult human small intestine (hSI), hIOs at passage 2 did not fully
recapitulate the expression level of genes such as OLFM4, an
intestinal stem cell (ISC) marker, or a panel of genes expressed by
Paneth cells that are responsible for host defense and digestive
function (Fig. 1c and Supplementary Table 1). Additional pas-
sages (up to 10 passages over 150 days) did not result in any
further maturation of hIOs, as assessed by the gene expression
levels of a panel of intestinal maturation markers, such as
OLFM4, DEFA5, SI, DPP4, LCT, and GIP (Fig. 1d).
In adults, the intestinal epithelium interacts with immune cells
in the intestinal mucosa to maintain intestinal homeostasis and
mucosal immunity15,16. We hypothesized that immune system
components, such as T lymphocytes, present in the intestinal
epithelium and lamina propria17, could play a role in the
maturation of the intestinal epithelium, and so we adapted our
hIO culture system to co-culture with immune cells, enabling
crosstalk between the hIOs and the immune cells via the soluble
factors secreted from each cell. Various cytokines and chemo-
kines were highly expressed in phorbol myristate acetate (PMA)/
ionophore-stimulated Jurkat T cells compared to non-stimulated
Jurkat T cells (Supplementary Fig. 3a, b). Therefore, hIOs were
placed onto Transwell inserts and introduced into 12-well plates
together with stimulated Jurkat T cells (Supplementary Fig. 4a).
The co-culture of hIOs and stimulated Jurkat T cells led to a
significant increase in organoid size, as well as to an increase in
the number of budding structures present on each organoid,
compared to the co-culture with non-stimulated Jurkat T cells
(Fig. 1e and Supplementary Fig. 4b, c). hIOs cultured in the
presence of conditioned medium (CM) taken from Jurkat T cells
also showed similar changes in morphology (Fig. 1e), suggesting
the involvement of secreted paracrine factors. Using Spearman’s
correlation analysis, we observed that the expression profile of co-
cultured hIOs is most closely related to that of hSI (Fig. 1f). This
finding was further supported by data obtained in a microarray
analysis of intestinal markers and genes involved in the defense
response and digestion (Fig. 1c).
IL-2/STAT3 signaling is required for hIO maturation. Next, we
assessed the levels of several cytokines in the CM of PMA/
ionophore-stimulated Jurkat T cells to identify the major secreted
factor in this co-culture system. Compared to unstimulated cells,
stimulated Jurkat T cells released significantly higher amounts of
IL-2 than other cytokines, including tumor necrosis factor alpha
(TNFα), IL-8, IL-22, IL-6, IL-1β, IL-11, EGF, OSM, and IL-10
(Fig. 2a and Supplementary Table 2). Interestingly, the
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05450-8
2 NATURE COMMUNICATIONS |  (2018) 9:3039 | DOI: 10.1038/s41467-018-05450-8 | www.nature.com/naturecommunications
corresponding IL-2 receptor (IL-2R) complex containing IL-2
receptor beta (IL-2Rβ) and gamma (IL-2Rγc) chains was
expressed in the hIOs and the levels of gene and protein
expression of receptor complex were increased upon co-culture
(Fig. 2b, c). To investigate the signaling profile more thoroughly,
we performed a phospho-kinase array analysis. Of the 43 kinases
included in the array, 21 kinases exhibited a noticeable difference
(>1.2-fold change) in their phosphorylation status when com-
paring the control and co-culture systems (Supplementary
Fig. 5a, b). Pathway enrichment analysis revealed that the IL-2-
mediated signaling pathway was one of the most heavily upre-
gulated pathways in the co-cultured hIOs (adjusted FDR < 0.001;
Supplementary Fig. 5c).
Having identified IL-2 as a candidate factor for promoting the
in vitro maturation of hIOs, we next applied recombinant human
IL-2 (rhIL-2) to our hIOs. The previously identified pattern of
phospho-activation could be recapitulated solely by the use of IL-
2 rather than Jurkat T cells, as assessed by the activation of
previously identified downstream effectors such as STAT3 and c-
Jun (Fig. 2d and Supplementary Fig. 5d, e). Treatment with IL-2
at a concentration of 1–8 ng/ml was sufficient to significantly
increase organoid size (Supplementary Fig. 6a). Further, hIOs
cultured with IL-2 significantly increased in size and the average
number of buds per hIO similar to those with CM of PMA/
ionophore-stimulated Jurkat T cells. This increase was completely
inhibited when the selective blockade of the IL-2 receptor was
induced by a combination of antibodies against IL-2Rβ and IL-
2Rγc (Fig. 2e).. Given that hIOs that have already been matured
in vitro by IL-2 treatment did not require a continuous supply of
IL-2 (Supplementary Fig. 7a–c), this in vitro maturation status of
hIOs did not appear to be a transient.
In the phospho-kinase array analysis, phosphorylation of
STAT3 (Y705) was the most substantially altered (3.3-fold
increase) upon IL-2 treatment (Supplementary Fig. 5d, e),
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Fig. 1 hPSC-derived hIOs undergo maturation during co-culture with immune cells. a Representative morphology and immunofluorescent staining of hIOs
(p0, p10) for gut-specific markers (SOX9, CDX2, and KLF5); the enterocyte marker, VIL1; the goblet cell marker, MUC2; the Paneth cell marker, LYZ; the
enteroendocrine cell marker, CHGA; and the epithelial marker, ECAD. Scale bar, 200 μm. b Principal component analysis (PCA) of differentially expressed
genes (>2-fold change) from microarray experiments comparing definitive endoderm cells (DE) (n= 3), hindgut cells (HG) (n= 3), hIOs (p0) (n= 3),
hIOs (p2) (n= 3), co-cultured hIOs (n= 3) and adult human small intestine (hSI) (n= 4). c Heatmaps of genes involved in the defense response, intestinal
markers and genes required for digestion, demonstrating that co-cultured hIOs are the cell type most similar to adult hSI. d qPCR analysis of the expression
of intestinal markers and maturation markers in hIO (p2, p8, p10) and hSI. e Representative images of morphological changes occurring in hIOs following
co-culture with PMA/ionophore-stimulated Jurkat T cells or treatment with stimulated Jurkat T cell-conditioned medium (CM). Scale bar, 1 mm.
Quantitative assessment of the size of hIOs after two passages; n= 9 (control), n= 11 (co-culture), n= 9 (CM) hIOs per group. PMA phorbol myristate
acetate, CI calcium ionophore. f Spearman’s correlation was used to cluster samples and generate a heatmap. Red indicating the highest level of similarity
between samples and blue indicates the lowest level of similarity. The dendrogram indicates that co-cultured hIOs are similar to hSI samples. Data are
presented as mean values of replicates ± SEM. **p < 0.01, *p < 0.05, according to t-test
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followed by the phosphorylation of AKT and P70 S6 Kinase,
implying the involvement of the STAT3 and mTOR signaling
pathways in hIO maturation (Supplementary Fig. 5f and Fig. 2d,
f). In support of this conclusion, the effect of IL-2 on hIO
growth was prevented by the addition of the specific small
molecule inhibitors of STAT3, S3I-201 or Stattic, or of
mTOR, rapamycin (Fig. 2g). We also found that treatment with
STAT3 activators, such as Colivelin or IL-22, promoted the
growth of hIOs with many crypt-like budding structures
(Supplementary Fig. 8a, b). These data suggest that the effect of
IL-2 on the morphology of hIOs is mediated by the activation of
STAT3 signaling.
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Fig. 2 IL-2 activates STAT3 pathway to induce the in vitro maturation of hIOs. a ELISA quantification of IL-2, IL-8, TNFα, IL-22, IL-6, IL-1β, IL-11, EGF, OSM,
and IL-10 concentrations in the culture supernatant of stimulated and unstimulated Jurkat T cells. Expression of IL-2R subunits as analyzed by RT-PCR
b and Western blot analyses c in co-cultured or IL-2-treated hIOs. d Phosphorylation levels of proteins from multiple signaling pathways in control, co-
cultured and IL-2-treated hIOs as reported by a human phospho-kinase array (upper panels). Analysis by functional interaction (FI) network highlighted a
significant enrichment of phospho-proteins in the mTOR and STAT3 signaling pathways (lower panels). In the FI network, arrows represent activating/
catalyzing connections, solid lines ending in a perpendicular line represent inhibition, solid lines represent complexes or inputs and dashed lines represent
predicted FI connections. e Representative images of the morphology of hIOs cultured in the presence of 1 ng/ml IL-2, a key component of the co-culture
system, or stimulated Jurkat T conditioned medium (CM) with or without IL-2R-inactivating antibodies (anti-IL-2Rβ, anti-IL-2Rγc) for two passages.
Quantitative assessment of the size of hIOs (left bottom) and the number of budding structure per hIO (right bottom); n= 12 hIOs per group.
f Representative Western blot analysis of p-STAT3, p-AKT and p-P70 S6 Kinase levels in co-cultured and IL-2-treated hIOs. g hIOs cultured in the
presence of IL-2 (1 ng/ml) with or without the addition of S3I-201 (5 μM), Stattic (1 μM) or Rapamycin (Rapa; 10 nM). Quantitative assessment of the size
of hIOs after one passage (14 days) (left bottom) and the number of budding structure per hIO (right bottom); n= 14 hIOs per group. Data are presented
as mean values of replicates ± SEM. ***p < 0.001, **p < 0.01, and *p < 0.05 according to t-test. Scale bar, 500 μm
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In vitro-matured hIOs more closely resemble the adult hSI. We
sought to further characterize the effect of IL-2 on the in vitro
maturation of hIOs by performing global gene expression pro-
filing using microarray to compare untreated hIOs, hIOs in co-
culture with stimulated Jurkat T cells, hIOs treated with IL-2 and
hSI (Supplementary Fig. 9a). Co-culture of hIOs with stimulated
Jurkat T cells was slightly more effective than the treatment of
hIOs with IL-2 in recapitulating the profile of hSI (55.9% of genes
shifted towards the profile of hSI vs 49.8% of genes shifted,
respectively). Statistical analyses, including PCA, hierarchical
clustering with the Canberra distance, and Spearman’s correla-
tion, revealed strong correlations between the expression profiles
of the co-cultured or IL-2-treated hIOs and the hSI (Supple-
mentary Fig. 9b–d). Gene Ontology (GO) enrichment analysis on
differentially expressed genes involved in intestinal maturation
after the co-culture or IL-2 treatment of hIOs revealed a sig-
nificant up-regulation of genes annotated with GO terms related
to cellular response to stimulus, defense response, regulation of
immune system process, and response to cytokines (Supple-
mentary Fig. 9e and Supplementary Table 1). Quantitative RT-
PCR (qPCR) analysis was performed for a number of mature
intestinal markers: CDX2, an intestine-specific marker; OLFM4,
an ISC marker of the mature intestine; the Paneth cell markers,
DEFA5, DEFA6, and LYZ; and the mature intestinal differentia-
tion markers KRT20, MUC13, SLC5A1, CREB3L3, DPP4, and
LCT (Fig. 3a). For most genes, the level of expression was highly
upregulated compared to control hIOs and was similar or at least
comparable to hSI. Interestingly, hPSC-derived hIOs further
matured in vitro by co-culture or by treatment with IL-2 showed
a similar level of maturation to human adult tissue-derived
intestinal organoids (hAT-IOs; Fig. 3a). Immunofluorescence
consistently detected the expression of the DEFA5, OLFM4,
MUC13, and KRT20 proteins only in hIOs matured in vitro by
co-culture or treatment with IL-2 and not in the control hIOs
(Fig. 3b). In addition, functional brush-border enzymes and
intestinal transporters, such as sucrase-isomaltase (SI), MDR1
and peptide transporter 1 (PEPT1), were exclusively expressed in
the co-cultured or IL-2-treated hIOs (Fig. 3c). The expression of
mature intestinal markers was completely inhibited upon block-
ing of IL-2 signaling (Supplementary Fig. 6b). To assess the
maturation status of hIOs based on global gene expression pat-
terns, we conducted PCA (Fig. 3d), hierarchical clustering of with
the Canberra distance (Fig. 3e), and Spearman’s correlation
(Fig. 3f) analyses using our original and publicly available RNA-
sequencing datasets of human fetal and adult small intestine
samples (Supplementary Table 3). These analyses consistently
demonstrated that the transcriptomes of the in vitro-matured
hIOs co-cultured or treated with IL-2 more closely resembled the
profile of the hSI than that of fetal small intestines.
hIOs matured in vitro display enhanced functionality. Because
the mature hSI plays a major role in drug absorption and
metabolism and expresses a diverse array of transporters and
drug-metabolizing enzymes18, we compared the expression pat-
terns of various transporters and metabolizing enzymes between
in vitro-matured hIOs and hSI. The main intestinal cytochrome
p450 enzymes, conjugation enzymes and transporters of the
solute carrier (SLC) family (uptake), and ATP-binding cassette
(ABC) family (efflux) were highly expressed in hSI, as expected
(Fig. 4a). Of the 40 analyzed enzymes and transporters, 27 (67.5
%) and 25 (62.5 %) were upregulated by at least 2-fold in the hIOs
matured by co-culture and treatment with IL-2, respectively; a
greater number than is seen in hAT-IOs (Fig. 4b). Next, we tested
the intestinal cell type-specific activity in the in vitro-matured
hIOs, such as the efficacy of transport and secretion function by
performing the various functional assays. hIOs have a function-
ally permeable intestinal epithelial barrier, as indicated by the
paracellular diffusion pattern of FITC-dextran (Fig. 4c). P-
glycoprotein (P-gp/MDR1/ABCB1) is a major efflux transporter
that affects the pharmacokinetics of a wide range of drugs and
xenobiotics19, and high P-gp expression was detected in the hIOs
matured in vitro by either co-culture or treatment with IL-2
(Fig. 4d). To directly assess the activity of P-gp, paclitaxel, a
prototypic substrate, was loaded to the basolateral side (outside)
of hIOs incubated under control and in vitro-matured conditions.
Following a 2 h incubation, the concentrations of paclitaxel at the
apical side (inside of hIOs) were increased approximately 2.3-fold
(p < 0.001) in the hIOs matured by co-culture and 3-fold (p <
0.001) in the hIOs matured by treatment with IL-2 when com-
pared to concentrations at the apical side in control hIOs
(Fig. 4d). The inhibition of P-gp activity by the addition of ver-
apamil, a calcium channel blocker, abrogated this increased level
of paclitaxel transport (Fig. 4d). Upon glucose stimulation, more
intracellular Ca2+ was released from the endoplasmic reticulum
(ER) in the co-cultured and IL-2-treated hIOs, which also
exhibited higher Ca2+ transient amplitudes (ΔF/F0 based on the
calcium indicator Fluo-4 AM) than were observed in the control
hIOs (Fig. 4e). These results are consistent with the high
expression level of the major glucose transporters of the intestine,
such as GLUT2 (SLC2A2), GLUT5 (SLC2A5), and SGLT1
(SLC5A1) (Fig. 4e), suggesting that the in vitro-matured hIOs
contain more glucose-responsive mature enterocytes. The
expression of cystic fibrosis transmembrane conductance reg-
ulator (CFTR) was significantly higher in the co-cultured and IL-
2-treated hIOs (Fig. 4f). The results of forskolin-induced swelling
(FIS) assays, which were used to measure the functional activity
of the CFTR anion channel20, verified these findings. We quan-
tified FIS of hIOs using real-time imaging microscopy and cal-
culated the total area of hIOs for each time point after the
forskolin induction. Upon stimulation with forskolin, more
swelling was observed in the co-cultured and IL-2-treated hIOs
than in the control hIOs, and FIS was blocked by the CFTR-
specific inhibitors CFTRinh-172 and GlyH-101 in both co-
cultured and IL-2-treated hIOs (Fig. 4f). Mucin and mucin
secreting goblet cells were identified more often in the co-cultured
or IL-2-treated hIOs compared to control hIOs by staining with
mucicarmine and periodic acid-Schiff (PAS) (Fig. 4g). We also
examined the secreted level of gastric inhibitory polypeptide
(GIP), one of the hormones produced by functionally matured
enteroendocrine cells21. These levels were significantly higher in
the co-cultured or IL-2-treated hIOs than in the control hIOs,
consistent with the observed up-regulation of GIP expression
(Fig. 4h). Together, these data indicate that the in vitro-matured
hIOs not only shifted their gene expression profiles towards that
of mature hSI, but also contained matured intestinal-specific cell
types with the appropriate physiological functionalities.
In vitro-matured hIOs retain maturation markers in vivo. To
assess the suitability of in vitro-matured hIOs for transplantation,
mature hIOs were injected under the kidney capsule of immu-
nodeficient NOD-SCID IL-2Rγcnull (NSG) mice. The near-
infrared fluorescent lipophilic dye, DiR, was used to label hIOs
to allow their quantitative detection in vivo. The transplanted
hIOs were confined inside of the kidney at 1 day post-trans-
plantation, as detected by DiR fluorescence intensity (Supple-
mentary Fig. 10a). The fluorescent signal was still detectable
1 week after transplantation (Fig. 5a). Analysis of the transplanted
hIOs both by fluorescent signal and by histological examination
revealed that only the hIOs matured in vitro by co-culture and by
treatment with IL-2 maintained the increased sizes after the
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transplantation (Fig. 5a and Supplementary 10b). Intestinal cell
type-specific markers were detected in all hIOs (Supplementary
Fig. 10c), whilst markers of intestinal maturation were evident
only in the transplants of in vitro-matured hIOs (Fig. 5b). DEFA5
and OLFM4 expression was exclusively observed in the co-
cultured and IL-2-treated hIOs and confirmed by co-staining
with Paneth cell marker (LYZ) and intestinal stem cell marker
(ASCL2), respectively, and RNA fluorescence in situ hybridiza-
tion (FISH) (Supplementary Fig. 11a, b). Quantitative analysis
also showed that there were significantly more DEFA5- and
OLFM4-positive cells in the in vitro-matured hIOs than in the
control hIOs (Fig. 5c). In addition, a brush-border enzyme, SI,
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Fig. 3 Co-cultured or IL-2-treated hIOs express the markers of mature small intestine. a qPCR analysis of the expression of markers of intestinal maturation
in control, co-cultured and IL-2-treated hIOs, human adult tissue-derived intestinal organoids (hAT-IOs) cultured in the presence or absence of
nicotinamide (NAM), and hSI. NAM was used to improve the culture efficiency of hAT-IOs. Fold changes in expression level are relative to control hIOs.
b Immunofluorescent staining of control, co-cultured and IL-2-treated hIOs with a proliferation marker (Ki-67), an epithelial marker (ECAD) and mature
intestinal markers (DEFA5, OLFM4, MUC13, and KRT20). Scale bar, 50 μm. c Immunofluorescent staining for the intestinal enzyme sucrase-isomaltase
(SI) and intestinal transporters (peptide transporter 1, PEPT1; multidrug resistance protein 1, MDR1). Scale bar, 50 μm. d PCA of the RNA-sequencing
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and the intestinal transporters MDR1 and PEPT1 were expressed
only in the in vitro-matured hIOs after short-term transplanta-
tion (Fig. 5d). These results suggest that hIOs matured in vitro
can retain their maturation status in vivo because they express the
intestinal maturation markers even after they are transplanted.
Given that the in vitro-matured hIOs maintained normal kar-
yotypes (Supplementary Fig. 12), we suggest that they may
represent an effective alternative source of cells for in vivo
applications.
Discussion
At present, it is possible to generate hIOs from two cell sources:
hPSCs and adult intestinal tissue. Although hAT-IOs are a well-
established technology and readily generate mature intestinal
epithelium from surgically resected samples or endoscopic biop-
sies, they have some limitations. Firstly, genetically engineering of
hAT-IOs is complex and inefficient, as it has to be performed
within the context of 3D culture. Secondly, hAT-IO culture
generates only the intestinal epithelium without the attendant
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Fig. 4 In vitro-matured hIOs have significantly enhanced functionalities. a Comparison of the gene expression of drug-metabolizing enzymes (phase I/II
enzymes) and intestinal transporters (ABC transporters and SLC transporters) among hIOs, hAT-IOs, and hSI. The graph represents the number of genes
with expression >2-fold when compared with the control hIOs. b Hierarchical clustering of the expression level of genes encoding intestinal enzymes and
transporters in control, co-cultured, and IL-2-treated hIOs, hAT-IOs, and hSI. c Paracellular permeability of hIOs incubated with 4 kDa FITC-Dextran and
40 kDa FITC-Dextran. Scale bar, 1 mm. d Expression levels of the transporter P-gp (MDR1, ABCB1) relative to control hIOs as assessed by qPCR (left panel).
Apical concentration of paclitaxel following 2 h incubation in the absence or presence of verapamil in control, co-cultured or IL-2-treated hIOs (right panel,
n= 20 per group). e Expression levels of the glucose transporters (GLUT2, GLUT5, SGLT1) in control, co-cultured, IL-2 treated hIOs, and hSI as assessed by
qPCR (left panels). Glucose-induced Ca2+ transients in real-time manner in control, co-cultured and IL-2 treated hIOs (middle panels). Mean values of
peak fluorescence intensity by using Fluo-4-AM calcium indicator (right panel) (n= 15 per group). f Expression levels of the CFTR in control, co-cultured,
IL-2 treated hIO and hSI as assessed by qPCR (left panel). Representative images of the morphological changes of hIOs after treatment with forskolin
(middle panel). Scale bar, 200 μm. Normalized forskolin-induced swelling of control, co-cultured, and IL-2 treated hIOs with or without CFTR inhibitors
(GlyH101+ CFTRinh 172) (right panel, n= 4 per group). g Mucicarmine staining for secreted mucin and acid mucopolysaccharide (black arrowheads), and
PAS staining for the mucous layer (black arrows) and mucous producing goblet cells. Scale bar, 50 μm. h Expression levels of intestinal hormone GIP of
control, co-cultured, and IL-2 treated hIOs and hSI (left panel). The levels of secreted GIP from enteroendocrine cells in hIOs ELISA for detection of, and
normalized to DNA content (right panel). Data are presented as mean values of replicates ± SEM. ***p < 0.001 according to t-test
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Fig. 5 In vitro-matured hIOs can retain their maturation status in vivo. a Ex vivo fluorescence images of the kidney of immunodeficient (NSG) mice
transplanted with DiR-labeled hIOs 1 week after transplantation using an IVIS imaging system (left panels). Quantification of the fluorescence intensity,
expressed as the average radiance of the DiR-labeled hIOs (right panels; n= 3). p s−1 cm−2 sr−1, photons per second per cm2 per steradian.
b Immunofluorescent staining for the intestinal maturation markers DEFA5, OLFM4, KRT20 and MUC13 in control, co-cultured and IL-2-treated hIOs
following transplantation. Adult human small intestine (hSI) tissues were used as controls. c The number of DEFA5+ and OLFM4+ cells in control, co-
cultured and IL-2-treated hIOs. Expression of DEFA5+ cells (left panel; n= 5) and OLFM4+ cells (right panel; n= 4). d Immunofluorescent staining for the
intestinal enzyme sucrase-isomaltase (SI) and intestinal transporters (peptide transporter 1, PEPT1; multidrug resistance protein 1, MDR1) in control, co-
cultured and IL-2-treated hIOs following transplantation. hSI tissues were used as controls. Data are presented as mean values of replicates ± SEM. *p <
0.05 and **p < 0.01 according to t-test
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mesenchymal components, in stark contrast to hPSC-derived
hIOs. As whole genome-scale genetic engineering in embryonic
and induced hPSCs is comparatively simple, the ability to gen-
erate fully mature, functional hIOs from hPSCs would allow the
combined use of these complementary technologies. hPSC-
derived hIOs therefore exhibit great potential for further studies
of human gut development, physiology, and disease, as well as
providing a readily accessible cell source for transplantation.
However, generating fully functionally mature hIOs from hPSCs
has until now proven to be technically challenging without the
use of in vivo maturation3,7,10, and exposing hIOs to a xeno-
biological environment for their maturation precludes their use in
clinical applications. Therefore, understanding the mechanism of
hIO maturation has been of great interest to recapitulate this
under conditions that would allow their clinical use.
Although various cell types are involved in the maturation and
maintenance of intestinal tissue in vivo, the main players are cells
in the intestinal epithelial lining and immune system22. Here we
report that the co-culture with T lymphocytes or the introduction
of an immune component, such as IL-2, to hPSC-derived hIO
culture is key for the in vitro maturation of hIOs. Our in vitro
maturation system of the intestine was constructed using hIOs
comprising both intestinal epithelial cells (IECs) and surrounding
stromal mesenchyme in combination with immune cells using a
layer-by-layer approach, thus recapitulating epithelial-stromal-
immune interactions. These cells are constantly communicating
with each other and are influenced by interactions with soluble
factors secreted by neighboring immune cells, which can main-
tain intestinal homeostasis and integrity1,23. Immune cells from
the lamina propria and intraepithelial lymphocytes express var-
ious cytokines, such as IL-1, IL-2, IL-6, IL-10, and TNFα, which
are known to stimulate proliferation and differentiation in
IECs24,25. Actually, we used multicolor FACS analysis to
demonstrate that more than half of the CD3+CD4+ and
CD3+CD8+ T cell populations in the isolated mouse intestinal
lamina propria secreted IL-2 (Supplementary Fig. 13a–e). Con-
sistent with this observation, IL-2 was first identified as a major
component in our in vitro maturation system. Recently, IL-2 was
reported to contribute not only to modulating the growth and
differentiation of immunocytes during inflammatory response
but also to the maintenance and repair of intestinal mucosa and
the epithelium26,27. Functional IL-2 receptors were endogenously
expressed in isolated primary human IECs and human IEC lines,
including Caco-2, HT-29, and T-84 cells, thus implying a phy-
siological role for IL-2 in regulating epithelial functions28,29. IL-2-
deficient mice develop a progressive inflammatory bowel disease
closely resembling human ulcerative colitis (UC)30,31, and UC
patients also exhibit a significant reduction in the expression of
IL-232. These results suggest that IL-2 may be important for the
control of the intestinal structure and mucosal immunity.
Our results indicate that rhIL-2 induced the in vitro matura-
tion of hIOs by binding to IL-2 receptors located on the surface of
cells in the hIOs, subsequently activating the STAT3 and mTOR
pathways. The in vitro maturation activity was abrogated by
selectively blocking the IL-2 receptors on the hIOs or treatment
with specific inhibitors for STAT3 and mTOR. IL-2 receptor
specificity for intestinal maturation was also assessed using
murine IL-2 and the murine intestinal organoid (mIO) system
from IL-2 receptor gamma chain disrupted NSG mice (Supple-
mentary Fig. 14a, b). However, more studies in the mIO system
are required. This result is consistent with the increased IEC
proliferation and regeneration via STAT3 after stimulation with
IL-2233,34 and a very recent study demonstrating the role of
mTOR signaling in promoting a proper IEC structure and
function35,36. To our knowledge, this is the first report demon-
strating the IL-2-mediated activation of the STAT3 and mTOR
pathways in intestinal maturation and its functional significance.
Although our in vitro data demonstrated that IL-2, as a mediator
of the immune system, promotes intestinal maturation, additional
in vivo experiments are necessary to clarify the mechanisms
involved.
Our results indicate that the in vitro-matured hIOs acquired
the morphological, molecular, and physiological hallmarks of
mature hSI. We are the first to demonstrate that the tran-
scriptome of in vitro-matured hIOs more closely resembles that
of the hSI than that of the fetal small intestine. Both co-culture
with human T lymphocytes and treatment with IL-2 significantly
enhanced the expression of Paneth cell-specific genes and pre-
viously described intestinal maturation markers, which were
expressed only after in vivo exposure7,10. Our in vitro-matured
hIOs exhibit comparable levels of expression of various trans-
porters and metabolizing enzymes to the hSI. Surprisingly, hAT-
IOs exhibited lower expression levels of major drug transporters
and metabolizing enzymes than were observed in the in vitro-
matured hIOs. This result was attributed to the regional dis-
tribution of these transporters and enzymes in hAT-IOs derived
from the human ileum, given that the expression of these genes is
reduced in the ileum than in the upper small intestine37. Tissue-
specific cells that are already differentiated undergo changes to
achieve their specific functionality through the maturation pro-
cess38,39. Generally, generating functional mature cells from
hPSCs is technically challenging, ultimately resulting in hPSC-
derived organoids of a less mature state40. However, we not only
observed an extensive shift in the transcriptome profile in the in
vitro-matured hIOs, but also showed the achievement of diverse
functionality of the in vitro-matured hIOs, by performing various
functional assays, including P-gp activity assay, glucose-
stimulated intracellular calcium response to assess glucose
transporter activity, FIS assay to assess CFTR activity, muci-
carmine, and PAS staining to detect mucus producing mature
goblet cells, and ELISA for GIP secreted from mature enter-
oendocrine cells. These findings are consistent with recent reports
that the maturation status influences cell type-specific func-
tions41,42. Therefore, the in vitro maturation method for hPSC-
derived hIOs provided in this study not only induce further
differentiation, but also promote maturation by achieving
intestinal cell type-specific functionality. Although the intestinal
epithelial cell diversity and the appropriate physiological func-
tionalities of the hSI are recapitulated in the in vitro-matured
hIOs, we believe that further studies will be required because
complex organ-like structures, such as the spatial relationships of
the crypt-villus axis, are not completely preserved.
Functional vessel formation and connection to the host vas-
culature are critical factors for successful engraftment43. Previous
studies have demonstrated that when hIOs derived from hPSCs
are transplanted underneath the mouse kidney capsule, they
differentiate into mature adult cell types in vivo within
6–8 weeks10. Unfortunately, few vascular endothelial cells origi-
nating from the hPSCs were identified in the engraftment, and
newly formed vessels failed to connect the vasculature of the
transplanted parenchymal tissue to that of the host. However, we
observed that the in vitro-matured hIOs in our system were able
to successfully induce neovascularization in host blood vessels
only 1 week after transplantation, even though no CD31-positive
cells were detected before the hIOs were transplanted (Supple-
mentary Fig. 10d–f). Although the mechanisms underlying the
process by which the co-cultured or IL-2-treated hIOs induced
neovascularization are not fully understood, the most likely
explanation is that the human vascular endothelial cells that
connected to the host vasculature were derived from the
mesenchyme adjacent to the co-cultured and IL-2-treated hIOs.
Consistent with this notion, we found that there were more
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laminated human mesenchyme (α-smooth muscle actin (α-
SMA)-positive cells) in the co-cultured and IL-2-treated hIOs
than in the control hIOs and that the mesenchyme of the co-
cultured and IL-2-treated hIOs expressed higher levels of vascular
endothelial growth factor (VEGF) (Supplementary Fig. 10d),
which are known to recruit blood vessels from adjacent tissue44.
Several studies have demonstrated that the AKT/mTOR and
STAT3 pathways are related to the regulation of vascularization
and vasculogenesis45,46. Therefore, downstream signaling events
in hIOs influenced by the co-culture or IL-2-treatment, such as
the AKT/mTOR and STAT3 pathways, may enable the hIOs to
prepare for the fast intracellular signaling that is required to
promote vascularization. However, this finding needs to be fur-
ther investigated to determine whether and why the transdiffer-
entiation of mesenchymal cells surrounding the hPSC-derived
hIOs into vascular endothelial cells is dependent on in vivo
transplantation, and this project is currently underway.
In summary, we report a simple method for forming mature
hIOs from hPSCs in vitro. Our study highlights the importance of
increasing the cellular complexity of existing organoid culture
systems and the appropriate physiological functionality in order
to better model adult human organ systems in vitro for facil-
itating the utilization of hIOs in various aspects of in vitro
applications, such as a drug evaluation and pharmacological
testing. Furthermore, this technology represents the first complete
workflow linking hiPSC biobanks, and thus the opportunity for
wide-scale genome editing, with the mature in vitro models of
adult intestinal physiology, disease and potential clinical
applications.
Methods
Cell culture and iPSC generation. Normal human fibroblasts (CRL-2097 and
IMR90) and human T lymphocytes (Jurkat T cells) were obtained from the
American Type Culture Collection. The H9 human embryonic stem cell (hESC)
line was purchased from the WiCell Research Institute (Madison, WI, USA).
Fibroblasts and hPSCs, including hESCs and hiPSCs, were cultured as described
previously47. Integration-free hiPSCs were generated from fibroblasts using Epi-
somal iPSC Reprogramming Vectors (Cat. No. A14703. Invitrogen, Carlsbad, CA,
USA) as described previously48. Five days after electroporation, fibroblasts were
seeded onto 6-well plates coated with Matrigel (BD Biosciences, San Diego, CA,
USA) at a density of 1 × 105/well in E8 medium (Stem Cell Technologies, Van-
couver, Canada). After 3 weeks, hiPSC colonies were picked and expanded for
further characterization. Jurkat T cells were cultured in RPMI 1640 medium
(Invitrogen) containing 10% fetal bovine serum (FBS, Invitrogen), 1% penicillin-
streptomycin (Invitrogen), and 2 mM L-glutamine (Invitrogen).
Differentiation of hPSCs into hIOs. hIOs were generated as described pre-
viously4,48. To induce definitive endoderm identity, well-maintained hPSCs should
be used and were treated with 100 ng/ml Activin A (R&D Systems, Minneapolis,
MN, USA) for 3 days in RPMI 1640 medium with increasing concentrations of 0,
0.2, and 2% defined fetal bovine serum (dFBS, HyClone, Thermo Fisher Scientific
Inc., Waltham, MA, USA). Cells were then treated for 4 days with RPMI 1640
medium containing 2% dFBS, 500 ng/ml FGF4 (R&D Systems), and 500 ng/ml
WNT3A (R&D Systems) to promote differentiation into 3D hindgut spheroids.
The spheroids were embedded in Matrigel (BD Biosciences) and cultured in hIO
medium composed of advanced DMEM/F12 medium (Invitrogen) containing 1 ×
B27 (Invitrogen), 500 ng/ml R-Spondin 1 (R&D Systems), 100 ng/ml EGF (R&D
Systems), and 100 ng/ml Noggin (R&D Systems), and then passaged every 2 weeks.
Culture and in vitro maturation of hIOs. For the human T lymphocyte co-culture
experiments, Jurkat T cells were stimulated with both 50 ng/ml phorbol myristate
acetate (PMA; Sigma-Aldrich, St. Louis, MO, USA) and 500 ng/ml calcium iono-
phore A23187 (Sigma-Aldrich) for 3 h. A Transwell polyester membrane insert
(pore size 0.4 μm, Corning, NY, USA) on which hIOs had been embedded within
Matrigel (BD Biosciences) was placed into the well of a 12-well plate containing
stimulated Jurkat T cells which had been seeded at 5 × 104/cm2 in hIO medium.
For achieving optimal efficiency and minimizing variations among cell lines, the
effect of interleukin 2 (IL-2) on hIOs was assessed by using well-differentiated and
characterized hIOs and adding freshly prepared rhIL-2 (R&D Systems) daily to
hIO medium at a concentration of 1–8 ng/ml (approximately 13–104 U/ml) for 2
passages. To inhibit IL-2 signaling, hIOs were treated with 1 μg/ml of anti-IL-2Rγc
or 3 μg/ml of anti-IL-2Rβ (R&D Systems). To block IL-2 downstream signal
transduction, either the mTOR inhibitor Rapamycin (10 nM; Sigma-Aldrich) or
one of the STAT3 inhibitors S3I-201 (10 μM; Sigma-Aldrich) or Stattic (1 μM;
Sigma-Aldrich) were also added. To activate STAT3 signaling, rhIL-22 (1, 10 ng/
ml, Peprotech, Rocky Hill, NJ, USA), and Colivelin (0.01, 1, 100 nM, Tocris
Bioscience, Ellisville, MO, USA) was added in hIO culture medium for 2 passages.
To estimate the size and number of budding structure of hIOs, we calculated the
surface area using horizontal cross-sections of the organoids.
Human phospho-kinase array. Protein phosphorylation was quantified using the
Proteome Profiler Human Phospho-Kinase Array Kit (ARY003, R&D Systems)
according to the manufacturer’s instructions. Protein extracts were prepared from
untreated hIOs, hIOs in co-culture with human T lymphocytes and hIOs treated
with 1 ng/ml rhIL-2. Briefly, hIOs were released from Matrigel using Cell Recovery
Solution (Corning) and rinsed with ice cold PBS. hIOs were lysed at 4 °C for 30 min
in Lysis Buffer of the Proteome Profiler Human Phospho-Kinase Array kit (R&D
Systems). The phospho-kinase array membranes were blocked, incubated with 200
μg of total protein from hIOs overnight at 4 °C, and then incubated further with
cocktails of biotinylated detection antibodies for 2 h at room temperature. Signal
was detected with the ECL Plus Western Blotting Detection System (GE Health-
care, Buckinghamshire, UK) and the images obtained underwent quantification by
densitometry with Image Gauge software (Fuji Photo Film GMBH, Tokyo, Japan)
to determine phospho-protein levels.
Measurement of cytokine secretion. Stimulated and unstimulated Jurkat T cells
were cultured for 2 days. Culture medium from each was collected and levels of
cytokines were determined using an enzyme-linked immunosorbent assay (ELISA)
IL-2, IL-8, TNFα, IL-22, IL-6, IL-1β, IL-11, EGF, IL-10 (R&D Systems), and OSM
(Abcam, CA, USA). ELISA was performed according to the manufacturer’s
instructions and as described previously49 prior to quantification with a Spectra
Max M3 microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Microarray. Microarray experiments were conducted according to the manu-
facturer’s protocol using the Low RNA input linear amplification kit, cRNA
cleanup module and one-color platform (Cy3) Whole Human Genome Microarray
4 × 44 K (Agilent Technologies, Santa Clara, CA, USA) as described previously49.
Gene expression data were processed using GeneSpringGX 7.3 (Agilent Technol-
ogies). The data were normalized using global scale normalization and differentially
expressed genes were selected on the basis of a >2-fold change.
RNA-sequencing (RNA-seq). RNA samples were analyzed using an Agilent 2100
Bioanalyzer system (Agilent Biotechnologies). Only samples of high-quality RNA
(RNA Integrity Number ≥ 7.5) were used in the following mRNA sample pre-
paration for sequencing. Libraries were prepared using Illumina TruSeq library
preparation per manufacturer specifications. Sample sequencing was performed on
Illumina HiSeq2500 machines (Illumina, San Diego, CA, USA) using the standard
Illumina RNA-Seq protocol with a read length of 2 × 100 bases. Sequencing quality
was assessed with the FastQC package and then the reads containing adapters were
trimmed using cutadapt and sickle for low-quality ends with a Phred quality
threshold score of 20. If the trimmed read length was less than 50 bp, it was
excluded. After filtering for sequencing errors, the processed reads were mapped to
the reference genome using HISAT2 (v2.0.5) with default parameter settings. The
human reference transcriptome annotation and reference genome from hg19 were
used. Gene expression quantification was performed with Cuffquant and Cuffnorm
(Cufflinks v2.2.1). Cuffdiff was used to analyze the differentially expressed genes
(DEGs) between samples.
Bioinformatic analysis. Hierarchical clustering and the heat map were generated
using MeV v 4.9.0 software. Other bioinformatic analyses were performed using
IPA analysis software (Ingenuity systems, Redwood City, CA, USA), the PAN-
THER (Protein ANalysis THrough Evolutionary Relationships, http://www.
pantherdb.org/) database and DAVID Bioinformatics Resources 6.7 (http://david.
abcc.ncifcrf.gov/). Differentially phosphorylated proteins were used for the analysis
and visualization of functional interaction networks. Core pathways in the network
were further analyzed using Reactome (Reactome FI software, http://apps.
cytoscape.org/apps/reactomefis). The functionally grouped gene ontology (GO)/
pathway was analyzed using the Cytoscape software platform (version 3.3.0, http://
www.cytoscape.org/what_is_cytoscape.html) with the ClueGO plug-in (Version
2.2.5, http://apps.cytoscape.org/apps/cluego). Principle component analysis (PCA)
was performed to visualize and quantify multi-dimensional variation between
samples. Principle components were calculated using the function ‘prcomp’ found
in the R (version 3.1.2) statistical programming language and plotted using the R
package. Hierarchical clustering based on a Mcquitty linkage method and the
Canberra distance was used to classify discrete samples according to the degree of
total transcriptional dissimilarity. Spearman correlation was applied as an addi-
tional assessment of the cumulative degree of correlation among microarray or
RNAseq datasets. We calculated the Spearman’s correlation in a pairwise variable
for all samples. The Spearman correlation was plotted as a heatmap using the
‘heatmap.2’ function in the R package ‘gplots’.
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Quantitative RT-PCR (qPCR). Total RNA was prepared using an RNeasy Kit
(Qiagen, Valencia, CA, USA) and reverse-transcribed using a Superscript III cDNA
synthesis kit (Invitrogen). qPCR was performed for triplicate samples using a 7500
Fast Real-time PCR system (Applied Biosystems). A house-keeping gene encoding
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal
control. RNA extracted from adult human small intestine (hSI) (Clonetech, Fre-
mont, CA, USA) was used as a positive control. The primers used in this study are
listed in Supplementary Table 4.
Western blotting. Cells were lysed with RIPA buffer and debris was removed by
centrifugation at 4 °C before 20 μg of total protein was separated by electrophoresis
on a 4–15% gradient gel (Ready Gel, Bio-Rad Laboratories, Hercules, CA) and
transferred to a PVDF membrane. The antibodies used in this study are listed in
Supplementary Table 5.
Processing and immunofluorescence analysis of cells and hIOs. hPSCs and
definitive endodermal cells were fixed in 4% paraformaldehyde (PFA) and then
permeabilized with 0.1% Triton X-100 prior to immunofluorescence analysis. hIOs
and tissues were fixed, cryo-protected in sucrose and frozen in optimal-cutting-
temperature (OCT) compound (Sakura Finetek, Tokyo, Japan). Frozen sections
were cut at a thickness of 10–20 μm using a cryostat microtome at −20 °C and
permeabilized with 0.1% Triton X-100 for immunofluorescence analysis as
described previously50. In brief, after being blocked with 4% BSA, samples were
incubated with primary antibodies (Supplementary Table 5) at 4 °C overnight
followed by incubation in the corresponding secondary antibodies for 1 h at room
temperature. Paraffin sections were deparaffinized, subjected to antigen retrieval
and stained in a similar fashion to OCT sections. Cell nuclei were visualized with
DAPI (4′,6-diamidino-2-phenylindole). Slides were examined with a fluorescence
microscope (IX51, Olympus, Japan), an Axiovert 200M microscope (Carl Zeiss,
Gottingen, Germany) and confocal microscope (Cat. No. FV1000 Live, OLYMPUS,
Tokyo, Japan).
Permeability assay. To determine permeability of hIOs, 4 kDa, and 40 kDa
fluorescein isothiocyanate-dextran (FITC-dextran, Sigma Aldrich) was used. hIOs
were washed with 5 times with PBS, and incubated with 1.25 μM FITC-Dextran for
30 min at 37 °C. FITC-dextran was removed, and hIOs were washed with PBS at
least 5 times. A fluorescence microscope (IX51, Olympus) was used for imaging.
P-glycoprotein (P-gp)/MDR1 activity assay. To determine P-glycoprotein
transporter activity, at least 20 hIOs per group were used in triplicate. hIOs were
placed into 4-well plates, washed three times with Hank’s balanced salt solution
(HBSS with calcium and magnesium, pH= 7.4; Invitrogen) containing 25 mM
HEPES and incubated at 37 °C for 30 min. The P-gp substrate paclitaxel, in DMSO
(10 μM, Sigma-Aldrich), was added to hIO cultures and incubated for 2 h on a
shaker at 50 r.p.m. in the presence or absence of verapamil, a P-gp inhibitor, in
phosphate-buffered saline (PBS; 50 μM, Sigma-Aldrich). After incubation, hIOs
were washed three times with HBSS and ruptured with an ultrasonic cell disruptor.
The homogenate was centrifuged at 13,000×g for 10 min at 4 °C, and the resulting
supernatant was collected for analysis. The concentration of paclitaxel in each
sample was quantitated by an LC-ESI/MS/MS analysis using a 3200 QTRAP LC-
MS/MS system (Applied Biosystems, Foster City, CA, USA) equipped with a Turbo
VTM Ion Spray source and an Agilent 1200 series HPLC system (Agilent
Technologies).
Calcium imaging with Fluo-4 AM. hIOs were loaded with Fluo-4 acetox-
ymethylester (fluo-4AM, 5 μM for 1 h, Molecular Probes, Eugene, Oregon, USA).
hIOs were then washed with Ca2+-free isotonic buffer (140 mM NaCl, 5 mM KCl,
10 mM HEPES, 5.5 mM D-Glucose, 2 mM MgCl2) and placed on the stage of
confocal microscope (FV1000 Live, Olympus). hIOs were stimulated with 50 mM
glucose (Sigma Aldrich) in Ca2+-free isotonic buffer. hIOs were excited at 488 nm,
and the signal emitted at 505–530 nm was recorded. The fluorescence intensity of
the region of interest (ROI) was calculated using FV1000 software.
Forskolin-induced swelling assay for CFTR function. To determine CFTR
activity of hIOs, forskolin-induced swelling (FIS) assay was used as described
previously20. hIOs were seeded in 4-well tissue culture plates with 10 μl Matrigel
dome and 1 ml of culture medium. Two days after seeding, 25 μM of forskolin
(Merck Millipore, Billerica, USA) was added in culture medium and hIOs were
analyzed by live microscopy imaging (IX83, Olympus) to measure CFTR function.
For CFTR inhibition, hIOs were pre-incubated with 100 μM CFTR Inhibitor-172
(Merck Millipore), and 100 μM CFTR Inhibitor II (GlyH-101, Merck Millipore) for
3 h. After pre-incubation, 25 μM forskolin was added and hIOs were directly
analyzed.
Mucicarmine and periodic acid-Schiff (PAS) staining. To detect mature goblet
cells, we performed mucicarmine and PAS staining. Histological analyses were
performed with 4% PFA fixed OCT-embedded organoid sections. Slides were
subjected to mucicarmine (abcam) and PAS staining (Microscopy PAS staining kit,
Merck Millipore) as recommended by the manufacturer.
Hormone secretion assay for GIP. hIOs were washed with PBS 5 times, and hIO
culture medium was added. After a 24-h incubation, the supernatant was har-
vested, and secreted GIP was measured using a human total GIP ELISA kit (Merck
Millipore). DNA was extracted from hIOs and quantified using Nanodrop
(Nanodrop2000c spectrophotometer, Thermo Fisher Scientific, Inc.). Total GIP
content was normalized to DNA content. Genomic DNA was prepared using a
DNeasy Kit (Qiagen).
Transplantation. Eight to twelve-week-old NOD-SCID IL-2Rγnull (NSG) mice
were used in all experiments (8–12 weeks old, Jackson Laboratories, Bar Harbor,
ME, USA). All mice were housed in a standard animal maintenance facility at a
constant temperature (20–22 °C) with a 12:12 h light: dark schedule. Ethical
approval was received for all experiments from the Institutional Animal Care and
Use Committee (IACUC) of KRIBB (Approval No: KRIBB-AEC-16206). Xeno-
grafting of hIOs under the kidney capsule was performed as described previously10.
Briefly, hIOs were embedded into purified collagen type I (Rat tail collagen; BD
Biosciences) for 12 h before transplantation. Mice were anesthetized with 2% iso-
flurane (Butler Schein, Dublin, OH, USA), and the left side of the mouse was then
prepared using isopropyl alcohol and povidone-iodine in the standard fashion. A
left subcostal incision was made to expose the kidney. The hIOs in the collagen
plug were then transplanted into the subcapsular space of the kidney. The kidney
was then returned to the peritoneal cavity and the mice were administered an IP
flush with Enrofloxacin (5 mg/kg; Daehan New Pharm Co., Hwaseong-si, Korea).
The skin was closed with a double layer and mice were kept warm with a heating
pad until they had recovered fully from the anesthesia. Mice were euthanized
humanely one week after transplantation and the xenografts were isolated for
analysis.
In vivo fluorescence imaging. To monitor the transplanted hIOs, hIOs were
incubated with 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide
(DiR, Invitrogen) in 4-well plates at 37 °C for 15 min. After washing with PBS,
hIOs were incubated with fresh medium and then transplanted under the kidney
capsule. To visualize fluorescence in vivo, the recipient mice (n= 3) were anes-
thetized with 2% inhaled isoflurane (Terrell™, Piramal Healthcare, Bethlehem, PA,
USA) one day after transplantation and placed into a light-sealed chamber con-
nected to a charge-coupled device camera. To confirm the exact size of the
transplanted hIOs, the kidneys of the recipient mice were isolated one week after
transplantation and placed in a light-sealed chamber connected to a charge-
coupled device camera. The fluorescence intensity of each region of interest was
measured with the In Vivo Imaging System (IVIS Lumina II, Xenogen Corp.,
Alameda, CA, USA) with emission at 780 nm and excitation at 750 nm.
In situ RNA hybridization and immunofluorescent staining. In situ RNA
hybridization was conducted using RNAscope® Fluorescent Multiplex Assay
(Advanced Cell Diagnostics, Hayward, CA) following the User Guide from
the manufacturer. Briefly, 4% PFA–fixed 10-μm-thick frozen transplanted hIOs
sections were mounted on SuperFrost® Plus slides (Thermo Fisher Scientific Inc.).
The samples applied target retrieval with boiling for 5 min and were treated by
Protease ΙΙΙ for 30 min at 40 °C. The slides were incubated with RNAscope® Hs-
DEFA5 and Hs-OLFM4 probes (Supplementary Table 6) for 2 h at 40 °C, and the
amplification followed the standard protocols. For simultaneous detection of
mRNAs and proteins, immunofluorescence staining was performed on the same
slide. The signal was visualized using an Olympus Spectroscopic Confocal Laser
Scanning Microscope (FV1000 Live, Olympus).
Measurement of episomal copy-number. hiPSC lysates were prepared using 1×
Taq buffer (Takara, Kyoto, Japan) and proteinase K at 55 °C for 3 h and were used
for qPCR analysis as described previously51. A known concentration of the pCXLE-
hFbx15-cont2 plasmid was used to create a standard curve. The copy number of
EBNA-1 and FBXO15 in each hiPSC line was calculated from the threshold cycle
(Ct) values obtained over six replicates.
Short tandem repeat (STR) and karyotype analysis. STR analysis was per-
formed by HumanPass, Inc. (Seoul, Korea) using genomic DNA isolated from
fibroblasts and the corresponding iPSC lines. G-banding karyotype analysis was
performed by GenDix, Inc. (Seoul, Korea).
In vivo differentiation via teratoma formation. A total of 1 × 106 cells were
mixed with Matrigel and injected subcutaneously into the dorso-lateral area of
BALB/c nude mice (6 weeks old, Orient Bio, Inc., Seongnam, Korea). After 8 to
10 weeks, the resulting teratomas were dissected, fixed in 4% PFA and embedded in
paraffin. Paraffin-embedded teratomas were sectioned and then stained with
hematoxylin and eosin solution (Sigma-Aldrich). Animal experiments were
approved by the IACUC of KRIBB (Approval No: KRIBB-AEC-15192).
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Isolation and culture of NSG murine intestinal organoids. Pieces of small
intestine (~0.5 mm) from NOD-SCID IL2 receptor γ chainnull (NSG) mice (The
Jackson Laboratory, Bar Harbor, ME, USA) were incubated for 20 min at room
temperature in Gentle Cell Dissociation Reagent (StemCells Inc., Newark, CA,
USA). Isolated crypts were obtained through a 70-μm strainer and seeded into
mixed solution with 1:1 growth factor-reduced (GFR) Matrigel (BD Biosciences)
and IntestiCult™ Organoid Growth Medium (StemCells Inc.) in 24-well Clear TC-
Treated Multiple Well Plates (Costar, Washington, DC, USA). The medium was
changed every 3–4 days, and mIOs were passaged every 1 week. To evaluate the
effects of murine IL-2 (mIL-2) on mIOs, organoids were treated with recombinant
mIL-2 (1–20 ng/ml, Peprotech). Organoid morphology was observed using
microscopy (DMI 4000B, Leica, Wetzlar, Germany).
Isolation and analysis of lamina propria lymphocytes. Isolation of mouse
lamina propria experiments were performed after approval by the Institutional
Animal Care and Use Committee (IACUC) of KRIBB (approval No: KRIBB-AEC-
17195), and adult C57BL/6 J mice (10 weeks old, Dae Han Bio Link Co., Ltd.,
Eumseong-gun, Chungcheongbuk-do, Korea) were used. Mouse small intestine
lamina propria lymphocytes were isolated from five independent mice per
experiment as described previously52. Isolated lamina propria lymphocytes were
incubated in protein transport inhibitor (GolgiStop, BD Biosciences) for 6 h, then
washed twice with staining buffer and blocked with Fc Blocking solution (BD
Biosciences). The cells were labeled with surface antibodies at 4 °C for 30 min
(Supplementary Table 5) and washed. For IL-2 staining, cells were subject to 20
min fixation at 4 °C using the fixation/permeabilization solution (BD Biosciences),
washed twice with staining buffer and incubated with anti-mIL-2 antibody diluted
in BD Perm/Wash (BD Biosciences) buffer for 1 h at 4 °C. Then, lamina propria
lymphocytes were analyzed on a FACSCalibur (BD Biosciences) according to the
manufacturer’s instructions. The data were analyzed with FlowJo V10 software
(FLOWJO, Ashland, OR, USA).
Statistical analysis. All results are expressed as mean ± standard error of the mean
(SEM), and all experiments were repeated at least three times. P values were
determined using two-tailed t-tests. All analyses of statistical significance were
calculated and compared with the control group unless otherwise stated.
Data availability. The data supporting the findings presented in this study are
included in the manuscript and supplementary files. All microarray data are
deposited in GEO under accession number GSE116738. Other relevant source data
are available from the authors on request.
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